Biotech Startups

cellvie develops Therapeutic Mitochondria Transplantation technology and products for patients requiring mitochondrial treatment. The company combines expertise across science, regulatory affairs, manufacturing, and business to advance this therapeutic platform.

2 investors

CellX Biosolutions develops a biological method that uses bacteria to break down PFAS ("forever chemicals"), positioned as an alternative to conventional disposal methods. The company operates in the environmental cleantech and biotech space.

2 investors

Centauri Therapeutics develops the Alphamer platform, a proprietary antibody recruiting molecule technology designed to redirect the immune system against disease targets. The platform is intended for treatment of life-threatening indications across multiple disease areas.

2 investors

Centrillion develops high-density DNA chips combined with AI-powered analysis to generate genomic and cellular data at scale for biological research. The platform enables researchers to ask thousands of variant questions in a single assay and decode genomes, cells, and tissues using AI models.

2 investors

Century Therapeutics develops allogeneic, iPSC-derived cell therapies using gene editing and protein engineering for autoimmune diseases including type 1 diabetes and cancer. The company aims to make cell therapies more effective, tolerable, accessible and affordable than existing treatments.

2 investors

Cepheid manufactures molecular diagnostic instruments and tests that automate PCR-based testing for infectious diseases, oncology, and human genetics. The company serves institutions ranging from central laboratories to near-patient settings with automated diagnostic solutions.

2 investors

Cephla provides laboratory/scientific instrumentation setups available through custom quotes. The company describes itself as a team focused on innovation and quality.

2 investors

Ceragen is a Canadian biotechnology company providing DNA and viral sequencing services to greenhouse and field growers to monitor crop health and manage plant disease. The company combines microbiome testing technology with practical reporting tools to help growers reduce uncertainty and improve crop performance.

2 investors

Avalo is a clinical-stage biotechnology company developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Its pipeline includes abdakibart (AVTX-009), tested in a Phase 2 trial for hidradenitis suppurativa, and AVTX-010, a long-acting next-generation anti-IL-1β antibody.

2 investors

Cerecura is a biotech company focused on developing RNA therapies to treat neurological disorders and neurodegeneration. The company leverages drug delivery expertise and neuroscience research to create next-generation treatments for patients with brain diseases.

2 investors

Certa Therapeutics develops targeted therapeutics to treat fibrotic diseases including scleroderma, chronic kidney disease, diabetic nephropathy, and focal segmental glomerulosclerosis. The company serves patients with serious, often life-threatening fibrotic conditions.

2 investors

Chainreactor builds patented modular benchtop bioreactors and accompanying software that replicate industrial-scale physics, letting biomanufacturers design, predict, and test cell behavior before scaling up production. It serves biotech and biomanufacturing companies as a "picks and shovels" hardware/software provider for scaling bioprocesses.

2 investors

Champions Oncology offers a KRAS-focused preclinical platform built on patient-derived xenograft (PDX) models screened with the pan-RAS(ON) inhibitor daraxonrasib, combining in vivo pharmacology with multi-omic characterization to study drug response and resistance. It serves pharma and biotech teams developing KRAS-directed cancer therapies for NSCLC, pancreatic (PDAC), and colorectal cancers, providing benchmarking, biomarker, and combination-strategy evidence.

2 investors

Irvine, CA based Alzheimer's drug company

2 investors

Cheiron is a pharmaceutical AI platform that synthesizes scientific literature, clinical evidence, regulatory documents, and safety data to provide verifiable insights for drug discovery, clinical development, medical affairs, and regulatory workflows in the biopharma industry.

2 investors

Chemon is a non-clinical contract research organization (CRO) that provides GLP-compliant efficacy and toxicity testing, quality assurance, and regulatory support for pharmaceuticals, agrochemicals, and chemicals. It serves clients seeking product approval and registration, offering custom non-clinical strategy and alternative testing services aligned with global regulatory standards.

2 investors

Chemtros is a research-focused specialty chemical manufacturer founded in 2006 that produces pharmaceutical intermediates and active pharmaceutical ingredients (APIs), electronic materials, industrial adhesives, and semiconductor materials for various industries. The company leverages accumulated synthesis expertise combined with blending technology to serve customers across pharmaceuticals, electronics, and advanced materials sectors.

2 investors

2 investors

CHONEX develops insect-derived biological products that enhance soil health, plant nutrition, and crop resilience to address challenges including salinity, drought, heat, and nutrient deficiency. The company serves growers by improving root systems and nitrogen use efficiency through a scalable closed-loop biological platform.

2 investors

Chorus Health creates digital healthcare solutions using data, design, and technology to improve patient engagement and outcomes.

2 investors

nChroma Bio is a genetic medicines company developing in vivo therapies that pair genetic cargoes with targeted delivery technologies. It takes a disease-first approach, designing durable treatments aimed at the biological drivers of diseases with high unmet need.

2 investors

Cianna Medical develops oncology products for breast cancer care, including targeted APBI (accelerated partial breast irradiation) therapy and wire-free tumor localization tools for lesions from breast to soft tissue. Its products are aimed at clinicians treating breast cancer patients.

2 investors

Advancing clinical candidates for cardiovascular, metabolic and kidney diseases. (NASDAQ: CINC) (Acquired by AstraZeneca)

2 investors

Circuit Clinical describes its team culture, employee benefits, and hiring, but the page provides no concrete detail about its products or services.

2 investors